Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 7/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.37 |
| ▸ | POLB | P06746 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.34 |
| ▸ | CCR6 | P51684 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL516156 | 0.86 | SLC6A2 (0.37) | SLC6A2SLC6A4CYP2D6ALDH1A1MEN1 | |
| SCHEMBL515947 | 0.86 | SMN1; SMN2 (0.35) | SLC6A2SLC6A4CYP2D6MEN1KMT2A | |
| SCHEMBL516134 | 0.82 | SMN1; SMN2 (0.47) | SLC6A2SLC6A4CYP2D6SLC6A3SMN1; SMN2 | |
| SCHEMBL14760363 | 0.76 | SMN1; SMN2 (0.49) | SLC6A2SLC6A4CYP2D6SLC6A3SMN1; SMN2 | |
| SCHEMBL516716 | 0.74 | LMNA (0.37) | CYP2D6CYP2C19SMN1; SMN2CYP1A2LMNA | |
| SCHEMBL9486483 | 0.70 | AKR1C1 (0.43) | SLC6A2SLC6A4CYP2D6MEN1KMT2A | |
| SCHEMBL516780 | 0.69 | HPGD (0.43) | SLC6A2SLC6A4MEN1KMT2ALMNA | |
| SCHEMBL516130 | 0.69 | PKM (0.40) | ALDH1A1MEN1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL515687 | 0.69 | SMN1; SMN2 (0.38) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL515953 | 0.68 | OPRM1 (0.43) | SLC6A2SLC6A4CYP2D6SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8455550-B2 | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products | PIERRE FABRE MEDICAMENT (FR) | 2013-06-04 | — | — | US | claimed |
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | claimed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | claimed |
| US-8455550-B2 | Derivatives of aminocyclobutane or aminocyclobutene, their method of preparation and their use as medical products | PIERRE FABRE MEDICAMENT (FR) | 2013-06-04 | — | — | US | disclosed |
| EP-2414323-B1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PF MEDICAMENT (FR) | 2013-03-13 | — | — | EP | disclosed |
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | PIERRE FABRE MEDICAMENT (FR) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029013-A1 | DERIVATIVES OF AMINOCYCLOBUTANE OR AMINOCYCLOBUTENE, THEIR METHOD OF PREPARATION AND THEIR USE AS MEDICAL PRODUCTS | CYP11B2, BCAT1, CYP11B1 | SLC6A2 3043/4885SLC6A4 3870/4885CYP2D6 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.